KHCM
AUTL

Kettle Hill Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Kettle Hill Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-89,792
Closed -$192K – 49
2022
Q3 		$192K Buy
+89,792
New +$266K 0.05% 67

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Kettle Hill Capital Management's AUTL Position: Q4 2022 in Review

Kettle Hill Capital Management sold out of Autolus Therapeutics (AUTL) in Q4 2022, closing a stake of 89,792 shares — an estimated $192K sold.

Kettle Hill Capital Management first reported a position in AUTL in Q3 2022 and held it in 1 quarter. The position peaked at $192K in Q3 2022. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

  • Kettle Hill Capital Management reported no remaining Autolus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kettle Hill Capital Management sold 89,792 Autolus Therapeutics shares in Q4 2022, an estimated $192K.
  • Kettle Hill Capital Management first reported a position in Autolus Therapeutics in Q3 2022 and held it in 1 quarter.
  • Kettle Hill Capital Management's Autolus Therapeutics position peaked at $192K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on Kettle Hill Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.